Cells expressing parathyroid hormone 1 receptor and uses thereof

Abstract

Disclosed herein are pluripotent stem cells cultured with one or more peptide and methods of isolating said stem cells. Also disclosed are methods of targeting the stem cells to a desired region or area within an organism. Also disclosed are methods of using the isolated stem cells for the improvement of fertility, for the promotion of hair growth, for the treatment or prevention of skin conditions, for the treatment or improvement of bone disorders, for the treatment of malignancies, and for the treatment of neurological disorders.

1 . (canceled) 
     
     
         2 . A composition comprising an isolated population of parathyroid hormone (PTH) receptor-positive pluripotent stem cells transfected with human telomerase reverse transcriptase (hTERT). 
     
     
         3 . The composition of  claim 2 , wherein said composition is formulated for topical administration to a subject. 
     
     
         4 . The composition of  claim 2 , wherein said composition is formulated as a cream, lotion, gel, or serum. 
     
     
         5 . The composition of  claim 2 , wherein said composition is formulated for parenteral administration to a subject. 
     
     
         6 . The composition of  claim 2 , wherein the composition comprises the isolated population of PTH receptor-positive pluripotent stem cells transfected with hTERT in quantities of 10,000 to 10,000,000 cells/mL. 
     
     
         7 . The composition of  claim 2 , wherein said composition reduces telomere shortening, increases cellular self-renewal, increases lifespan, reduces fine lines in the face, reduces wrinkles in the face, or reduces skin aging. 
     
     
         8 . The composition of  claim 2 , wherein said composition increases telomere activity. 
     
     
         9 . The composition of  claim 2 , wherein said isolated population of PTH receptor-positive pluripotent stem cells are viable. 
     
     
         10 . The composition of  claim 2 , wherein said isolated population of PTH receptor-positive pluripotent stem cells are not viable. 
     
     
         11 . The composition of  claim 2 , wherein said isolated population of PTH receptor-positive pluripotent stem cells are dried, desiccated, or lyophilized. 
     
     
         12 . The composition of  claim 2 , wherein said composition is a pharmaceutical. 
     
     
         13 . The composition of  claim 2 , wherein said composition is a cosmetic. 
     
     
         14 . The composition of  claim 2 , wherein the isolated population of PTH receptor-positive pluripotent stem cells express parathyroid hormone type 1 receptor (PTH1R). 
     
     
         15 . The composition of  claim 2 , wherein the isolated population of PTH receptor-positive pluripotent stem cells are positive for CD90 and CD133; positive/negative for CD29, CD34, CD105, and CD106; and negative for SSEA-3, CD200, and CD45. 
     
     
         16 . The composition of  claim 2 , wherein the isolated population of PTH receptor-positive pluripotent stem cells are isolated from peripheral blood of a subject. 
     
     
         17 . The composition of  claim 2 , further comprising a pharmaceutically acceptable carrier. 
     
     
         18 . A method of treating an age-related disorder, comprising:
 identifying a subject having an age-related disorder; and   administering to the subject the composition of  claim 2 .   
     
     
         19 . The method of  claim 18 , wherein the age-related disorder is osteoporosis, arthrosis, glucose intolerance, insulin resistance, reduced heart, circulatory, or lung function, cardiovascular disease, a neurodegenerative disease, loss of memory, loss of neuromuscular coordination, or decrease of longevity. 
     
     
         20 . The method of  claim 18 , wherein administration of the composition reduces telomere shortening, increases cellular self-renewal, increases lifespan, reduces fine lines or wrinkles, or reduces aging in the subject. 
     
     
         21 . The method of  claim 18 , wherein the composition is administered to the subject once weekly, once monthly, or once annually.